APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radionuclide Drug Conjugate(RDC)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Radionuclide Drug Conjugate(RDC) Market Outlook and Growth Opportunities 2026

29 December 2025196 pages

Choose your research edition.

Industry ResearchRadionuclide Drug Conjugate(RDC) Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Radionuclide Drug Conjugate(RDC) Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Radionuclide Drug Conjugate(RDC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radionuclide Drug Conjugate(RDC) Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Radionuclide Drug Conjugate(RDC) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Radionuclide Drug Conjugate(RDC) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Radionuclide Drug Conjugate(RDC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Radionuclide Drug Conjugate(RDC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Radionuclide Drug Conjugate(RDC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Radionuclide Drug Conjugate(RDC) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Radionuclide Drug Conjugate(RDC) market include China Tongfang Pharmaceuticals, Zhihe Biotechnology, Yuanda Pharmaceuticals, Novartis, Kelun Biotech, Hengrui, Fulian Pharmaceuticals, Dongcheng Pharmaceuticals and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Radionuclide Drug Conjugate(RDC) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Radionuclide Drug Conjugate(RDC) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Radionuclide Drug Conjugate(RDC) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Radionuclide Drug Conjugate(RDC) market.

Radionuclide Drug Conjugate(RDC) Segment by Company

China Tongfang Pharmaceuticals

Zhihe Biotechnology

Yuanda Pharmaceuticals

Novartis

Kelun Biotech

Hengrui

Fulian Pharmaceuticals

Dongcheng Pharmaceuticals

Bayer

Telix Pharmaceuticals

Lantheus

Curium

Radionuclide Drug Conjugate(RDC) Segment by Type

Therapy

Diagnosis

Radionuclide Drug Conjugate(RDC) Segment by Application

Prostate Cancer

Neuroendocrine Cancer

Other

Radionuclide Drug Conjugate(RDC) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Radionuclide Drug Conjugate(RDC) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Radionuclide Drug Conjugate(RDC) key companies, revenue, market share, and recent developments.

3. To split the Radionuclide Drug Conjugate(RDC) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Radionuclide Drug Conjugate(RDC) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Radionuclide Drug Conjugate(RDC) significant trends, drivers, influence factors in global and regions.

6. To analyze Radionuclide Drug Conjugate(RDC) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radionuclide Drug Conjugate(RDC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radionuclide Drug Conjugate(RDC) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radionuclide Drug Conjugate(RDC).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radionuclide Drug Conjugate(RDC) industry.

Chapter 3: Detailed analysis of Radionuclide Drug Conjugate(RDC) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Radionuclide Drug Conjugate(RDC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Radionuclide Drug Conjugate(RDC) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Radionuclide Drug Conjugate(RDC) Industry Trends Table 2. Radionuclide Drug Conjugate(RDC) Industry Drivers Table 3. Radionuclide Drug Conjugate(RDC) Industry Opportunities and Challenges Table 4. Radionuclide Drug Conjugate(RDC) Industry Restraints Table 5. Global Radionuclide Drug Conjugate(RDC) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Radionuclide Drug Conjugate(RDC) Revenue Share by Company (2021-2026) Table 7. Global Radionuclide Drug Conjugate(RDC) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Radionuclide Drug Conjugate(RDC) Key Company Manufacturing Base & Headquarters Table 9. Global Radionuclide Drug Conjugate(RDC) Company, Product Type & Application Table 10. Global Radionuclide Drug Conjugate(RDC) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Radionuclide Drug Conjugate(RDC) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Therapy Table 15. Significant Companies of Diagnosis Table 16. Global Radionuclide Drug Conjugate(RDC) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Radionuclide Drug Conjugate(RDC) Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Radionuclide Drug Conjugate(RDC) Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Type (2021-2026) Table 20. Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Prostate Cancer Table 22. Significant Companies of Neuroendocrine Cancer Table 23. Significant Companies of Other Table 24. Global Radionuclide Drug Conjugate(RDC) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Radionuclide Drug Conjugate(RDC) Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Radionuclide Drug Conjugate(RDC) Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Application (2021-2026) Table 28. Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Application (2027-2032) Table 29. Global Radionuclide Drug Conjugate(RDC) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Radionuclide Drug Conjugate(RDC) Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Region (2021-2026) Table 32. Global Radionuclide Drug Conjugate(RDC) Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Region (2027-2032) Table 34. Global Radionuclide Drug Conjugate(RDC) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Radionuclide Drug Conjugate(RDC) Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Radionuclide Drug Conjugate(RDC) Sales Value Market Share by Country (2021-2026) Table 37. Global Radionuclide Drug Conjugate(RDC) Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Radionuclide Drug Conjugate(RDC) Sales Value Market Share by Country (2027-2032) Table 39. China Tongfang Pharmaceuticals Company Information Table 40. China Tongfang Pharmaceuticals Business Overview Table 41. China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 43. China Tongfang Pharmaceuticals Recent Development Table 44. Zhihe Biotechnology Company Information Table 45. Zhihe Biotechnology Business Overview Table 46. Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Product Portfolio Table 48. Zhihe Biotechnology Recent Development Table 49. Yuanda Pharmaceuticals Company Information Table 50. Yuanda Pharmaceuticals Business Overview Table 51. Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 53. Yuanda Pharmaceuticals Recent Development Table 54. Novartis Company Information Table 55. Novartis Business Overview Table 56. Novartis Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Novartis Radionuclide Drug Conjugate(RDC) Product Portfolio Table 58. Novartis Recent Development Table 59. Kelun Biotech Company Information Table 60. Kelun Biotech Business Overview Table 61. Kelun Biotech Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Kelun Biotech Radionuclide Drug Conjugate(RDC) Product Portfolio Table 63. Kelun Biotech Recent Development Table 64. Hengrui Company Information Table 65. Hengrui Business Overview Table 66. Hengrui Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Hengrui Radionuclide Drug Conjugate(RDC) Product Portfolio Table 68. Hengrui Recent Development Table 69. Fulian Pharmaceuticals Company Information Table 70. Fulian Pharmaceuticals Business Overview Table 71. Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 73. Fulian Pharmaceuticals Recent Development Table 74. Dongcheng Pharmaceuticals Company Information Table 75. Dongcheng Pharmaceuticals Business Overview Table 76. Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 78. Dongcheng Pharmaceuticals Recent Development Table 79. Bayer Company Information Table 80. Bayer Business Overview Table 81. Bayer Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Bayer Radionuclide Drug Conjugate(RDC) Product Portfolio Table 83. Bayer Recent Development Table 84. Telix Pharmaceuticals Company Information Table 85. Telix Pharmaceuticals Business Overview Table 86. Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 88. Telix Pharmaceuticals Recent Development Table 89. Lantheus Company Information Table 90. Lantheus Business Overview Table 91. Lantheus Radionuclide Drug Conjugate(RDC) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Lantheus Radionuclide Drug Conjugate(RDC) Product Portfolio Table 93. Lantheus Recent Development Table 94. Curium Company Information Table 95. Curium Business Overview Table 96. Curium Radionuclide Drug Conjugate(RDC) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Curium Radionuclide Drug Conjugate(RDC) Product Portfolio Table 98. Curium Recent Development Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Radionuclide Drug Conjugate(RDC) Product Image Figure 2. Global Radionuclide Drug Conjugate(RDC) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radionuclide Drug Conjugate(RDC) Market Size (2021-2032) & (US$ Million) Figure 4. Global Radionuclide Drug Conjugate(RDC) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Therapy Image Figure 8. Diagnosis Image Figure 9. Global Radionuclide Drug Conjugate(RDC) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Radionuclide Drug Conjugate(RDC) Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Type (2021-2032) Figure 12. Prostate Cancer Image Figure 13. Neuroendocrine Cancer Image Figure 14. Other Image Figure 15. Global Radionuclide Drug Conjugate(RDC) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Radionuclide Drug Conjugate(RDC) Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Application (2021-2032) Figure 18. Global Radionuclide Drug Conjugate(RDC) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Radionuclide Drug Conjugate(RDC) Sales Value (2021-2032) & (US$ Million) Figure 21. North America Radionuclide Drug Conjugate(RDC) Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Radionuclide Drug Conjugate(RDC) Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Radionuclide Drug Conjugate(RDC) Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Radionuclide Drug Conjugate(RDC) Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Radionuclide Drug Conjugate(RDC) Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Radionuclide Drug Conjugate(RDC) Sales Value (2021-2032) & (US$ Million) Figure 27. South America Radionuclide Drug Conjugate(RDC) Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Radionuclide Drug Conjugate(RDC) Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Radionuclide Drug Conjugate(RDC) Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Therapy
  • Diagnosis
Applications
  • Prostate Cancer
  • Neuroendocrine Cancer
  • Other
Companies covered
  • China Tongfang Pharmaceuticals
  • Zhihe Biotechnology
  • Yuanda Pharmaceuticals
  • Novartis
  • Kelun Biotech
  • Hengrui
  • Fulian Pharmaceuticals
  • Dongcheng Pharmaceuticals
  • Bayer
  • Telix Pharmaceuticals
  • Lantheus
  • Curium

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Radionuclide Drug Conjugate(RDC) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Radionuclide Drug Conjugate(RDC) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Radionuclide Drug Conjugate(RDC) Market Dynamics
  1. 2.1 Radionuclide Drug Conjugate(RDC) Industry Trends
  2. 2.2 Radionuclide Drug Conjugate(RDC) Industry Drivers
  3. 2.3 Radionuclide Drug Conjugate(RDC) Industry Opportunities and Challenges
  4. 2.4 Radionuclide Drug Conjugate(RDC) Industry Restraints
3 Radionuclide Drug Conjugate(RDC) Market by Company
  1. 3.1 Global Radionuclide Drug Conjugate(RDC) Company Revenue Ranking in 2025
  2. 3.2 Global Radionuclide Drug Conjugate(RDC) Revenue by Company (2021-2026)
  3. 3.3 Global Radionuclide Drug Conjugate(RDC) Company Ranking (2024-2026)
  4. 3.4 Global Radionuclide Drug Conjugate(RDC) Company Manufacturing Base and Headquarters
  5. 3.5 Global Radionuclide Drug Conjugate(RDC) Company Product Type and Application
  6. 3.6 Global Radionuclide Drug Conjugate(RDC) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Radionuclide Drug Conjugate(RDC) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Radionuclide Drug Conjugate(RDC) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Radionuclide Drug Conjugate(RDC) Market by Type
  1. 4.1 Radionuclide Drug Conjugate(RDC) Type Introduction
  2. 4.1.1 Therapy
  3. 4.1.2 Diagnosis
  4. 4.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Type
  5. 4.2.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Type (2021-2032)
  7. 4.2.3 Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Type (2021-2032)
5 Radionuclide Drug Conjugate(RDC) Market by Application
  1. 5.1 Radionuclide Drug Conjugate(RDC) Application Introduction
  2. 5.1.1 Prostate Cancer
  3. 5.1.2 Neuroendocrine Cancer
  4. 5.1.3 Other
  5. 5.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Application
  6. 5.2.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Application (2021-2032)
  8. 5.2.3 Global Radionuclide Drug Conjugate(RDC) Sales Value Share by Application (2021-2032)
6 Radionuclide Drug Conjugate(RDC) Regional Value Analysis
  1. 6.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Radionuclide Drug Conjugate(RDC) Sales Value (2021-2032)
  7. 6.3.2 North America Radionuclide Drug Conjugate(RDC) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Radionuclide Drug Conjugate(RDC) Sales Value (2021-2032)
  10. 6.4.2 Europe Radionuclide Drug Conjugate(RDC) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Radionuclide Drug Conjugate(RDC) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Radionuclide Drug Conjugate(RDC) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Radionuclide Drug Conjugate(RDC) Sales Value (2021-2032)
  16. 6.6.2 South America Radionuclide Drug Conjugate(RDC) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Radionuclide Drug Conjugate(RDC) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Radionuclide Drug Conjugate(RDC) Sales Value Share by Country, 2025 VS 2032
7 Radionuclide Drug Conjugate(RDC) Country-level Value Analysis
  1. 7.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Radionuclide Drug Conjugate(RDC) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Radionuclide Drug Conjugate(RDC) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Radionuclide Drug Conjugate(RDC) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Radionuclide Drug Conjugate(RDC) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Radionuclide Drug Conjugate(RDC) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 China Tongfang Pharmaceuticals
  2. 8.1.1 China Tongfang Pharmaceuticals Company Information
  3. 8.1.2 China Tongfang Pharmaceuticals Business Overview
  4. 8.1.3 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  6. 8.1.5 China Tongfang Pharmaceuticals Recent Developments
  7. 8.2 Zhihe Biotechnology
  8. 8.2.1 Zhihe Biotechnology Company Information
  9. 8.2.2 Zhihe Biotechnology Business Overview
  10. 8.2.3 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Product Portfolio
  12. 8.2.5 Zhihe Biotechnology Recent Developments
  13. 8.3 Yuanda Pharmaceuticals
  14. 8.3.1 Yuanda Pharmaceuticals Company Information
  15. 8.3.2 Yuanda Pharmaceuticals Business Overview
  16. 8.3.3 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  18. 8.3.5 Yuanda Pharmaceuticals Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Radionuclide Drug Conjugate(RDC) Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Kelun Biotech
  26. 8.5.1 Kelun Biotech Company Information
  27. 8.5.2 Kelun Biotech Business Overview
  28. 8.5.3 Kelun Biotech Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Kelun Biotech Radionuclide Drug Conjugate(RDC) Product Portfolio
  30. 8.5.5 Kelun Biotech Recent Developments
  31. 8.6 Hengrui
  32. 8.6.1 Hengrui Company Information
  33. 8.6.2 Hengrui Business Overview
  34. 8.6.3 Hengrui Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hengrui Radionuclide Drug Conjugate(RDC) Product Portfolio
  36. 8.6.5 Hengrui Recent Developments
  37. 8.7 Fulian Pharmaceuticals
  38. 8.7.1 Fulian Pharmaceuticals Company Information
  39. 8.7.2 Fulian Pharmaceuticals Business Overview
  40. 8.7.3 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  42. 8.7.5 Fulian Pharmaceuticals Recent Developments
  43. 8.8 Dongcheng Pharmaceuticals
  44. 8.8.1 Dongcheng Pharmaceuticals Company Information
  45. 8.8.2 Dongcheng Pharmaceuticals Business Overview
  46. 8.8.3 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  48. 8.8.5 Dongcheng Pharmaceuticals Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bayer Radionuclide Drug Conjugate(RDC) Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Telix Pharmaceuticals
  56. 8.10.1 Telix Pharmaceuticals Company Information
  57. 8.10.2 Telix Pharmaceuticals Business Overview
  58. 8.10.3 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  60. 8.10.5 Telix Pharmaceuticals Recent Developments
  61. 8.11 Lantheus
  62. 8.11.1 Lantheus Company Information
  63. 8.11.2 Lantheus Business Overview
  64. 8.11.3 Lantheus Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Lantheus Radionuclide Drug Conjugate(RDC) Product Portfolio
  66. 8.11.5 Lantheus Recent Developments
  67. 8.12 Curium
  68. 8.12.1 Curium Company Information
  69. 8.12.2 Curium Business Overview
  70. 8.12.3 Curium Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Curium Radionuclide Drug Conjugate(RDC) Product Portfolio
  72. 8.12.5 Curium Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst